Tscan Therapeutics Stock Buy Hold or Sell Recommendation

TCRX Stock  USD 1.74  0.05  2.79%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Tscan Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Tscan Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Tscan Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out Tscan Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.
In addition, we conduct extensive research on individual companies such as Tscan and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Execute Tscan Therapeutics Buy or Sell Advice

The Tscan recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Tscan Therapeutics. Macroaxis does not own or have any residual interests in Tscan Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tscan Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Tscan TherapeuticsBuy Tscan Therapeutics
Strong Sell

Market Performance

Very WeakDetails

Volatility

Relatively riskyDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

HighDetails

Economic Sensitivity

Slowly supersedes the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

FrailDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Tscan Therapeutics has a Mean Deviation of 3.4, Standard Deviation of 5.22 and Variance of 27.26
We provide advice to complement the current expert consensus on Tscan Therapeutics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Tscan Therapeutics is not overpriced, please validate all Tscan Therapeutics fundamentals, including its cash and equivalents, and the relationship between the price to book and cash flow from operations . Please also confirm Tscan Therapeutics price to earning to double-check your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Tscan Therapeutics Trading Alerts and Improvement Suggestions

Tscan Therapeutics generated a negative expected return over the last 90 days
Tscan Therapeutics may become a speculative penny stock
Tscan Therapeutics has high historical volatility and very poor performance
Tscan Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 2.82 M. Net Loss for the year was (127.5 M) with loss before overhead, payroll, taxes, and interest of (2.03 M).
Tscan Therapeutics currently holds about 125.6 M in cash with (110.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Tscan Therapeutics has a frail financial position based on the latest SEC disclosures
Over 91.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Acquisition by Baker Bros. Advisors Lp of 758094 shares of Tscan Therapeutics at 1.95 subject to Rule 16b-3

Tscan Therapeutics Returns Distribution Density

The distribution of Tscan Therapeutics' historical returns is an attempt to chart the uncertainty of Tscan Therapeutics' future price movements. The chart of the probability distribution of Tscan Therapeutics daily returns describes the distribution of returns around its average expected value. We use Tscan Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tscan Therapeutics returns is essential to provide solid investment advice for Tscan Therapeutics.
Mean Return
-1.28
Value At Risk
-7.51
Potential Upside
6.33
Standard Deviation
5.22
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tscan Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Tscan Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument, such as Tscan Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Tscan Therapeutics back and forth among themselves.
Shares
Abrdn Plc2024-12-31
883.7 K
State Street Corp2024-12-31
800.9 K
Dc Funds, Lp2024-12-31
630 K
Morgan Stanley - Brokerage Accounts2024-12-31
412.9 K
Northern Trust Corp2024-12-31
322.1 K
Dimensional Fund Advisors, Inc.2024-12-31
280 K
Tocqueville Asset Management L.p.2024-12-31
260.9 K
Goldman Sachs Group Inc2024-12-31
160.7 K
Bank Of America Corp2024-12-31
150.1 K
Ecor1 Capital, Llc2024-12-31
M
Blackrock Inc2024-12-31
M
Note, although Tscan Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tscan Therapeutics Cash Flow Accounts

202020212022202320242025 (projected)
Investments(4.2M)(9.9M)(4.2M)(64.0M)(52.6M)(50.0M)
Change In Cash(7.0M)131.1M(41.4M)13.3M45.3M29.8M
Free Cash Flow(7.3M)(58.6M)(70.7M)(64.5M)(114.6M)(108.9M)
Depreciation1.2M3.3M5.1M5.4M4.1M3.6M
Other Non Cash Items2K9.2M260K(315K)(2.0M)(1.9M)
Capital Expenditures4.2M9.9M4.2M3.1M3.8M4.9M
Net Income(26.1M)(48.6M)(66.2M)(89.2M)(127.5M)(121.1M)
End Period Cash Flow35.4M166.4M125.1M138.4M183.7M126.7M

Tscan Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tscan Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tscan Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tscan stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-1.25
β
Beta against Dow Jones0.31
σ
Overall volatility
3.89
Ir
Information ratio -0.23

Tscan Therapeutics Volatility Alert

Tscan Therapeutics exhibits very low volatility with skewness of -1.96 and kurtosis of 10.16. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tscan Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tscan Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Tscan Therapeutics Fundamentals Vs Peers

Comparing Tscan Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tscan Therapeutics' direct or indirect competition across all of the common fundamentals between Tscan Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tscan Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tscan Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Tscan Therapeutics to competition
FundamentalsTscan TherapeuticsPeer Average
Return On Equity-0.65-0.31
Return On Asset-0.26-0.14
Operating Margin(55.21) %(5.51) %
Current Valuation(94.26 M)16.62 B
Shares Outstanding52.31 M571.82 M
Shares Owned By Insiders0.82 %10.09 %
Shares Owned By Institutions90.50 %39.21 %
Number Of Shares Shorted2 M4.71 M
Price To Earning23.45 X28.72 X
Price To Book0.41 X9.51 X
Price To Sales34.97 X11.42 X
Revenue2.82 M9.43 B
Gross Profit(2.03 M)27.38 B
EBITDA(119.74 M)3.9 B
Net Income(127.5 M)570.98 M
Cash And Equivalents125.6 M2.7 B
Cash Per Share5.22 X5.01 X
Total Debt65.31 M5.32 B
Debt To Equity0.04 %48.70 %
Current Ratio7.53 X2.16 X
Book Value Per Share4.26 X1.93 K
Cash Flow From Operations(110.82 M)971.22 M
Short Ratio5.80 X4.00 X
Earnings Per Share(1.14) X3.12 X
Target Price9.71
Number Of Employees19418.84 K
Beta0.91-0.15
Market Capitalization98.47 M19.03 B
Total Asset371.12 M29.47 B
Retained Earnings(375.1 M)9.33 B
Working Capital256.77 M1.48 B
Net Asset371.12 M
Note: Acquisition by Baker Bros. Advisors Lp of 758094 shares of Tscan Therapeutics at 1.95 subject to Rule 16b-3 [view details]

Tscan Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tscan . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Tscan Therapeutics Buy or Sell Advice

When is the right time to buy or sell Tscan Therapeutics? Buying financial instruments such as Tscan Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Tscan Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Health Management Thematic Idea Now

Health Management
Health Management Theme
Major hospitals and healthcare providers. The Health Management theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.